Register
Login:
Share:
Email Facebook Twitter


London South East - Oil & Gas Investor Evening: Malcy, Echo, Savannah, SDX
Andrew Knott, #SAVP speaks at London South East's Oil & Gas event


Physiomics Share Chat (PYC)



Share Price: 3.85Bid: 3.70Ask: 4.00Change: 0.00 (0.00%)No Movement on Physiomics
Spread: 0.30Spread as %: 8.11%Open: 3.85High: 3.85Low: 3.85Yesterday’s Close: 3.85


Share Discussion for Physiomics


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.85
Interesting AZenica/Merck RNS today
Mon 10:54
nts receiving Lynparza remained progression-free at three years compared to 27% on placebo following platinum-based chemotherapy

Lynparza is the only PARP inhibitor to demonstrate an improvement in progression-free survival as 1st-line maintenance treatment for advanced ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced detailed results from the Phase III SOLO-1 trial testing Lynparza(olaparib) tablets as a maintenance treatment for patients with newly-diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemoth
 
Ralphiebabe
Posts: 1,113
Opinion:No Opinion
Price:3.90
Re: Morning
Sun 18:53
Riddled, reading my charts, sp should start to tick up this week, hopefully Monday or Tuesday.
riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.90
RE: Morning
Sun 14:09
riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.90
Morning
Sun 14:08
Great work

Also some good tweets from InnovateUK ( whom we get grants from)
Ralphiebabe
Posts: 1,113
Opinion:No Opinion
Price:3.90
Merck
Sun 13:00
Confirmation from Merck that PYC has been involved with any of the regimes being displayed at ESMO conference, would be a bonus.
Also, if the decision making using VT pre clinical, or VT Clinical was helpful and cost effective to them in time and money.
Chrisatrdg
Posts: 1,342
Opinion:Strong Buy
Price:3.90
RE: Merck
Sat 22:00
Good find Ralphiebabe look forward to seeing their posters.
Ralphiebabe
Posts: 1,113
Opinion:No Opinion
Price:3.90
Merck
Sat 21:38
Merck oncology updates at conference, wonder if PYC involved with any.

European Society for Medical Oncology (ESMO) conference in Munich, Germany, Merck KGaA, Darmstadt, Germany will be presenting 39 abstracts in eight therapeutic agents across 14 tumor types, a “company record”. Ahead of the presentation at the Presidential Symposium on Sunday, October 21.

http://www.pharmexec.com/esmo-spotlight-james-campbell-merck

Quote from James Campell:-

I think any leading company in our industry has to lean in the direction of being even more externally focused, even more connected to the external innovation eco-system, and being even more inclined to think boldly about new approaches to how we can best develop our science and our pipeline. For all the talent we have in-house, there are always going to be brilliant ideas in the external world that we need to tap into and access. We can achieve the very best results by connecting our ideas and in-house talent with the external world to drive our business towards the future
Chrisatrdg
Posts: 1,342
Opinion:Strong Buy
Price:3.90
RE: Chris
Wed 21:00
Thanks riddler - In normal circumstances that is what I would do but because of my main investment - Summit (SUMM) which tanked on their DMD phase 2 failure earlier this year I have no further funds but do believe that PYC will come good.
riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.90
Chris
Wed 18:33
Maybe worth averaging down?
Chrisatrdg
Posts: 1,342
Opinion:Strong Buy
Price:3.90
RE: SP Close
Wed 17:19
My apologise the % has moved to plus 2.63% clearly I did not refresh my screen however I am still optimistic for PYC.
Chrisatrdg
Posts: 1,342
Opinion:Strong Buy
Price:3.90
SP Close
Wed 17:16
Good to see 10.53% up today on SP hopefully the start of a turning point for PYC supported by good results & a positive future.I currently have 44,600 shares at a cost of £3.3k & currently showing a loss of £1.6k (48.72% down).I am hoping that this will reverse in the next 6 months.
riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.80
Annual report..bottom para GSK imho
16 Oct '18
Ralphiebabe
Posts: 1,113
Opinion:No Opinion
Price:3.80
Forecast
16 Oct '18
woody2002
Posts: 2,219
Opinion:No Opinion
Price:3.80
RE: Woody
15 Oct '18
Yeah been reading up mate saw your posts. Cheers.
riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.80
Woody
15 Oct '18
Worth reading annual report today too

Did u see my notes last week? Or shall i re post?

Ps.i hold 970k for clarity
woody2002
Posts: 2,219
Opinion:No Opinion
Price:3.80
Took a punt
15 Oct '18
Bought In with just under 130k shares today. Hopefully this is the floor...GLA
riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.80
Albino _ Annual report
15 Oct '18
Yep..somejuicy hints
Ialso did some detailed notes which i posted here a few days ago if you search back
Albino
Posts: 749
Opinion:No Opinion
Price:3.80
RNS Glance
15 Oct '18
Had a glance at the RNS report on the company website.

Looks good to me.
riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.80
Potential
14 Oct '18
highlights:

• Agreement signed with Merck KGaA for 500k Euro for consulting services in 2018

• Signed contracts with two further undisclosed large pharmaceutical companies with total value of £105k

• Signed contracts with two biotech companies (one in Aug 2018, after the period end) with total value £103k

• Awarded a second Innovate UK Grant in as many years, in the field of personalised cancer treatment

• Recruited new scientific team member to expand capacity to deliver client projects

• Marketing efforts increased including comprehensive update of the website and attendance and participation at industry conferences

• Presented at AACR, one of the world's largest oncology focused conferences

"The Company made considerable progress last year and there is a renewed sense of momentum in the business. Following the deal with Merck KGaA, the team led by Dr Jim Millen secured further contracts in H2. This success is underpinned by acceptance of the use of modelling and simulation in the R&D process and the evolution of our Virtual Tumour technology to take advantage of this. This performance has continued into the new financial year with a healthy pipeline of new opportunities underpinned by existing contracts.
riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.80
Ralph
13 Oct '18
Yep. £250k from Merck plus £55k August and HALF of the deals DINCE Dec 2017 will fall into NEW financial year
I reckon we have done £350k so far and conservatively on for £750k ( 50% increase on this year) plus i reckon we will get detailed AGM statement in November and new deals
Ralphiebabe
Posts: 1,113
Opinion:No Opinion
Price:3.80
RE: From Ceo interview
13 Oct '18
At 3:35 of video, from time of Merck deal, approx half of the value of contracts will come in first half results for 2019. If that's half of Merck plus the other 2 contracts plus Grant, we could be at £250k - £300k now.
riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.80
From Ceo interview
13 Oct '18
Courtesy of Stockomist

#PYC $PYC Physiomics
'Very excited for the future'
'Game changer for Physiomics'
'Really great momentum building up'
'Significant potential for Personalised Med'
'...attending more Conferences'
Run-rate Rev £0.75m implies valuation of £7.5-15.0m based on publically listed peers
riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.80
CEO interview last week
13 Oct '18
riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.80
Ans
13 Oct '18
current cash and currently contracted projects are projected to cover all budgeted expenses during this period. In addition to currently contracted projects the Company anticipates a number of new clients as well as repeat business from some existing clients.
riddler
Posts: 82,146
Premium Chat Member
Opinion:No Opinion
Price:3.80
No positives?..
13 Oct '18
¢ Total income (revenue and grant income) increased 90% to £512,899 (2017: £270,465)

• Second half income (six months to 30 June 2018) increased 162% to £371,370 compared with the first half (six months to 31 December 2017: £141,529)

• The operating loss before exceptional costs decreased 47% to £260,391 (2017 £489,190); exceptional costs were £nil (2017: £41,362)

• The loss after taxation decreased 54% to £183,341 (2017: £400,526)




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.